Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Inmed Pharmaceuticals Inc (OP: IMLFF )

4.880 USD UNCHANGED
Last Price Updated: 4:06 PM EST, Nov 11, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.880
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 4.880
Today's Range 4.880 - 4.880
52wk Range 0.1084 - 8.940
Shares Outstanding 170,851,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe
From PR Newswire
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
From PR Newswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
+35.18%
+35.18%
6 Month
+17.87%
+17.87%
1 Year
+1985.47%
+1985.47%

More News

Read More
InMed to Participate at Virtual Conferences in January 2021
From PR Newswire
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
From PR Newswire
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
From PR Newswire
InMed Announces Election of Directors
From PR Newswire
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
From PR Newswire
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
From PR Newswire
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results
From PR Newswire
IIROC Trade Resumption - IN
From PR Newswire
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.